Bayer Kogenate FS
Bayer HealthCare, Biological Products Division

Contact Search Press Sitemap  
HomePatients & CaregiversHealthcare ProfessionalsPrescribing Information
Prescribing Information
Important Safety Information
Administration
HCP Video
Product Benefits
Efficacy
Clinical Publications
Simplicity
Safety
Hemophilia Awards
EZ-Log
Bayer Factor Solutions
Rep Finder
Summer Camps
Patient Education Materials
HCP Resources
HCP FAQ
Bayer Links
Bayer Global
Living with Hemophilia
   General Conditions of Use
Privacy Statement
Imprint
  
 
  

Efficacy

Clinical Publications

Several clinical trials demonstrate the efficacy of Kogenate® FS in hemophilia A. Click on the links below to read the full text of these trials.





Bayer Hemophila Awards
Bayer provides grants
to early career investigators, fellows in training, and other allied healthcare professionals.
Learn More


 
  

Kogenate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness, and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. For important safety and use information, please see the full prescribing information.

Please consult your health care provider prior to making any lifestyle changes. The images used on this site do not necessarily represent actual Hemophilia patients.